The NK1 antagonist aprepitant compared with the 5HT3 antagonist ondansetron for prevention of postoperative nausea and vomiting

被引：0
|
作者：
Candiotti, Keith A. [1 ]
Verma, Usha [1 ]
Diemunsch, Pierre [1 ]
Apfel, Christian [1 ]
Carides, Alexandra [1 ]
Reiss, Theodore [1 ]
机构：
[1] Univ Miami, Miller Sch Med, Miami, FL 33152 USA
来源：
OBSTETRICS AND GYNECOLOGY | 2007年 / 109卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：26S / 26S
页数：1
相关论文
共 50 条
  • [1] A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting
    Gan, Tong J.
    Apfel, Christian C.
    Kovac, Anthony
    Philip, Beverly K.
    Singla, Neil
    Minkowitz, Harold
    Habib, Ashraf S.
    Knighton, Jennifer
    Carides, Alexandra D.
    Zhang, Hong
    Horgan, Kevin J.
    Evans, Judith K.
    Lawson, Francasca C.
    ANESTHESIA AND ANALGESIA, 2007, 104 (05): : 1082 - 1089
  • [2] Antagonist of 5HT3 receptors zofran (ondansetron) in prevention of nausea and vomiting in cancer patients on cytostatic treatment
    Perevodchikova, NI
    Volkova, MA
    Gorbunova, VA
    Manzyuk, LV
    Marenich, AF
    Smirnova, NB
    TERAPEVTICHESKII ARKHIV, 1996, 68 (02) : 30 - 34
  • [3] Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting:: effect of gender on treatment response
    Hesketh, PJ
    Grunberg, SM
    Herrstedt, J
    de Wit, R
    Gralla, RJ
    Carides, AD
    Taylor, A
    Evans, JK
    Horgan, KJ
    SUPPORTIVE CARE IN CANCER, 2006, 14 (04) : 354 - 360
  • [4] Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
    P. J. Hesketh
    S. M. Grunberg
    J. Herrstedt
    R. de Wit
    R. J. Gralla
    A. D. Carides
    A. Taylor
    J. K. Evans
    K. J. Horgan
    Supportive Care in Cancer, 2006, 14
  • [5] Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
    Chawla, SP
    Grunberg, SM
    Gralla, RJ
    Hesketh, PJ
    Rittenberg, C
    Elmer, ME
    Schmidt, C
    Taylor, A
    Carides, AD
    Evans, JK
    Horgan, KJ
    CANCER, 2003, 97 (09) : 2290 - 2300
  • [6] PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING USING ONDANSETRON, A NEW, SELECTIVE, 5-HT3 RECEPTOR ANTAGONIST
    LEESER, J
    LIP, H
    ANESTHESIA AND ANALGESIA, 1991, 72 (06): : 751 - 755
  • [7] Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
    Lim, Chae Seong
    Ko, Young-Kwon
    Kim, Yoon-Hee
    Park, Sang-Il
    Kim, Jae-Kook
    Kim, Myoung-Joong
    Kim, Hyun-Joong
    KOREAN JOURNAL OF ANESTHESIOLOGY, 2013, 64 (03) : 212 - 217
  • [8] NK1 receptor antagonist aprepitant: active antiemetic for the prevention of chemotherapy-induced delayed nausea and vomiting
    Kawahara, Masaaki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 33P - 33P
  • [9] TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING AFTER OUTPATIENT SURGERY WITH THE 5-HT3 ANTAGONIST ONDANSETRON
    SCUDERI, P
    WETCHLER, B
    SUNG, YF
    MINGUS, M
    DUPEN, S
    CLAYBON, L
    LESLIE, J
    TALKE, P
    APFELBAUM, J
    SHARIFIAZAD, S
    WILLIAMS, MF
    ANESTHESIOLOGY, 1993, 78 (01) : 15 - 20
  • [10] An oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy
    Pendergrass, K
    Hargreaves, R
    Petty, KJ
    Carides, AD
    Evans, JK
    Horgan, KJ
    DRUGS OF TODAY, 2004, 40 (10) : 853 - 863
12345